GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Accumulated other comprehensive income (loss)

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Accumulated other comprehensive income (loss) : $0.28 Mil (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. IntelliPharmaCeutics International's Accumulated other comprehensive income (loss) for the quarter that ended in Aug. 2023 was $0.28 Mil.

IntelliPharmaCeutics International's quarterly Accumulated other comprehensive income (loss) stayed the same from Feb. 2023 ($0.28 Mil) to May. 2023 ($0.28 Mil) and stayed the same from May. 2023 ($0.28 Mil) to Aug. 2023 ($0.28 Mil).

IntelliPharmaCeutics International's annual Accumulated other comprehensive income (loss) stayed the same from Nov. 2020 ($0.28 Mil) to Nov. 2021 ($0.28 Mil) and stayed the same from Nov. 2021 ($0.28 Mil) to Nov. 2022 ($0.28 Mil).


IntelliPharmaCeutics International Accumulated other comprehensive income (loss) Historical Data

The historical data trend for IntelliPharmaCeutics International's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Accumulated other comprehensive income (loss) Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.28 0.28 0.28 0.28

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.28 0.28 0.28

IntelliPharmaCeutics International Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


IntelliPharmaCeutics International Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry
Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.